Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year. Proteon also announces the appointment of board member Gregory D. Phelps as Chairman of the Board of Directors.
"Our lead product, PRT-201, represents a highly innovative approach to addressing the significant medical challenges associated with vascular access in ESRD patients, and we are excited about the progress that we have made to date," said Timothy P. Noyes, President and CEO of Proteon. "We are now actively enrolling patients into two separate double-blind, placebo-controlled Phase 1/2 human clinical trials utilizing PRT-201 in AVF and AVG surgical settings. Greg's appointment to Chairman of the Board provides our team with even greater access to his wealth of strategic and operational experience at an important stage of Proteon's development."
"I am very happy to assume the role as Chairman of Proteon and to take a more active role in the progress of Proteon," said Greg Phelps. "I have enjoyed working with Tim Noyes, the Board and the management team over the last two years, and Proteon's development programs are exceptionally promising."